It might be too early to tell for ponatinib, but my impression was that rates of pancreatitis were higher than we've seen with the others. We should probably get a better idea of the side effect profile once the PACE trial is complete.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.